Constitutive TNF-α signaling in neonates is essential for the development of tissue-resident leukocyte profiles at barrier sites

FASEB J. 2019 Oct;33(10):10633-10647. doi: 10.1096/fj.201900796R. Epub 2019 Jun 29.

Abstract

Newborn infants have a high disposition to develop systemic inflammatory response syndromes (SIRSs) upon inflammatory or infectious challenges. Moreover, there is a considerable trafficking of hematopoietic cells to tissues already under noninflammatory conditions. These age-specific characteristics suggest a hitherto unappreciated crucial role of the vascular endothelium during the neonatal period. Here, we demonstrate that healthy neonates showed already strong endothelial baseline activation, which was mediated by a constitutively increased production of TNF-α. In mice, pharmacological inhibition of TNF-α directly after birth prevented subsequent fatal SIRS but completely abrogated the recruitment of leukocytes to sites of infection. Importantly, in healthy neonates, blocking TNF-α at birth disrupted the physiologic leukocyte trafficking, which resulted in persistently altered leukocyte profiles at barrier sites. Collectively, these data suggest that constitutive TNF-α-mediated sterile endothelial activation in newborn infants contributes to the increased risk of developing SIRS but is needed to ensure the postnatal recruitment of leukocytes to organs and interfaces.-Bickes, M. S., Pirr, S., Heinemann, A. S., Fehlhaber, B., Halle, S., Völlger, L., Willers, M., Richter, M., Böhne, C., Albrecht, M., Langer, M., Pfeifer, S., Jonigk, D., Vieten, G., Ure, B., von Kaisenberg, C., Förster, R., von Köckritz-Blickwede, M., Hansen, G., Viemann, D. Constitutive TNF-α signaling in neonates is essential for the development of tissue-resident leukocyte profiles at barrier sites.

Keywords: endothelium; leukocyte trafficking; neonatal immunity; newborn infant; sepsis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Newborn
  • Case-Control Studies
  • Disease Models, Animal
  • Endothelium, Vascular / immunology
  • Etanercept / pharmacology
  • Female
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Immunosuppressive Agents / pharmacology
  • Infant, Newborn / blood*
  • Infant, Newborn / immunology*
  • Infant, Premature
  • Leukocytes / drug effects
  • Leukocytes / immunology*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Monocytes / immunology
  • Signal Transduction / immunology
  • Systemic Inflammatory Response Syndrome / blood
  • Systemic Inflammatory Response Syndrome / immunology
  • Systemic Inflammatory Response Syndrome / prevention & control
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / blood*
  • Tumor Necrosis Factor-alpha / immunology*

Substances

  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha
  • Etanercept